Liquidia Technologies (LQDA)
(Real Time Quote from BATS)
$10.03 USD
-0.24 (-2.34%)
Updated Sep 20, 2024 11:00 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Liquidia Technologies, Inc. [LQDA]
Reports for Purchase
Showing records 41 - 60 ( 132 total )
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Split Hatch-Waxman Decision Sparks Litigation Stalmate; D/g to UNDERPERFORM
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Hatch-Waxman Litigation Decision Now In Hand-Next Steps For Yutrepia
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Stay Decision Request for ?793 Patent Was Long Shot; Keeping Focused on Hatch-Waxman
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Looking to Hatch-Waxman Decision Expected by October 2022?Yutrepia Next Steps
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q2: LQDA Expects HW Decision Before End of 30mo Stay; YUTREPIA Launch to Follow
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
IPR ?793 Patent Victory a Positive, But Focus Remains on Hatch-Waxman Litigation in 2022; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
''793 IPR Ruling; Final Approval/Launch Timing Rests On District Court Decision
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Highlights: Insights into the PAH Commercial & Clinical Landscape
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Tyvaso DPI Approval Shifts LQDA Focus on Hatch-Waxman Trial
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Patent Litigation Clarity Expected in 2022-Paths Forward for Yutrepia
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q1: YUTREPIA Launch Following Potential HW Decision Before End of 30mo Stay
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Yutrepia Near-Term 2022 Added Clarity - Interpreting Patent Litigation Implications
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY21: HW Trial Begins Mar. 28, YUTREPIA Launch Anticipated in Late 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Recommendation to Deny Summary Judgement, HW Litigation Ensues March 28
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
PAH Platform Positioned to Capitalize on Roger Jeffs? Stewardship; PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A